Stock Price Quote

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE3284.90-33.8 (-1.02 %)
PREV CLOSE ( ) 3318.70
OPEN PRICE ( ) 3255.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3053
TODAY'S LOW / HIGH ( )3255.60 3329.00
52 WK LOW / HIGH ( )1924.3 3515.95
NSE3295.00-25 (-0.75 %)
PREV CLOSE( ) 3320.00
OPEN PRICE ( ) 3300.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 3295.00 (366)
VOLUME 105723
TODAY'S LOW / HIGH( ) 3258.60 3331.60
52 WK LOW / HIGH ( )1921 3515.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924
Management Info
Renu Sud Karnad - Chairman Bhushan Akshikar - Managing Director
Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email askus@gsk.com / in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

15May GlaxoSmithKline Pharmaceuticals inform
In compliance with the provisions of Regulation 24A of SEBI LODR Amendme..
15May GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 47 of the Listing Obligations and Disclosure Requ..
15May GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 30(6) of Schedule III, of the Listing Obligations..
13May GlaxoSmithKline Pharmaceuticals inform
GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board..
13May GlaxoSmithKline Pharmaceuticals submit
Pursuant to Regulation 30 read with Part A of Schedule Ill of SEBI (List..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit2601.49190.6
Gross Profit 3549 12484.4
Operating Profit 370213118.5
Net Sales 9660.837234.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  10524.65 (3.40%)
M.Cap ( in Cr)25950.13
Abbott India (BSE)
peergroup  31650.00 (0.55%)
M.Cap ( in Cr)66797.18
RPG Life Sciences (BSE)
peergroup  2339.50 (4.07%)
M.Cap ( in Cr)3878.32
Concord Biotech (BSE)
peergroup  2115.00 (2.66%)
M.Cap ( in Cr)22133.13
Onesource Specialty (BSE)
peergroup  2019.10 (2.19%)
M.Cap ( in Cr)22749.88

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 5.17%
FI/BANKS/INSURANCE 2.6%
NON-INSTITUTION 12.69%
GOVERNMENT 0%
FII 0%

About Glaxosmithkline Pharmaceuticals Ltd.

Glaxosmithkline Pharmaceuticals Ltd. was incorporated in the year 1924. Its today's share price is 3284.9. Its current market capitalisation stands at Rs 56095.42 Cr. In the latest quarter, company has reported Gross Sales of Rs. 40971.88 Cr and Total Income of Rs.38660.52 Cr. The company's management includes S Williams, Anup Wadhawan, P R Somasundaram, Sunita Maheshwari, Juby Chandy, Manu Anand, Bhushan Akshikar, Renu Sud Karnad, Ajay Nadkarni.

It is listed on the BSE with a BSE Code of 500660 , NSE with an NSE Symbol of GLAXO and ISIN of INE159A01016. It's Registered office is at Gsk House, Dr. Annie Besant Road,Worli,Mumbai-400030, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Lovelock & Lewes, Price Waterhouse & Co, Price Waterhouse & Co Bangalore LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.